AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03885544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled processed red meat diet
Description: The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
Study NCT02054208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord blood derived mesenchymal stem cells
Description: Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
Study NCT02054208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 2mL
Description: Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
Study NCT03692871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
Study NCT03778684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body mass index
Description: Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
Study NCT01635348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor skill gait exercise
Description: The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
Study NCT01635348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic gait intervention
Description: The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
Study NCT01433302 — intervention group
Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: 5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
Study NCT00487474 — intervention group
Intervention type: DEVICE
Intervention: DL6049 (injectable poly-L-lactic acid)
Description: Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
Study NCT01545973 — intervention group
Intervention type: OTHER
Intervention: Skin Moistening, Skin Denuding
Description: Application of normal saline to skin and Tape stripping of the superficial skin
Study NCT02526108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFT
Description: Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
Study NCT04167072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent removal
Description: This is a procedural intervention in which the stent will be removed via endoscopy.
Study NCT04167072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent removal
Description: This is a procedural intervention in which the stent will be removed via endoscopy.
Study NCT02990507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVEED: Arm rotation, video display
Description: Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
Study NCT02990507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVEED: Arm rotation, without video display
Description: Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
Study NCT02990507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVEED: Leg rotation, arm-energy input, video display
Description: Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
Study NCT02990507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVEED: Leg rotation, arm-energy input, without video display
Description: Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
Study NCT04318236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERMES (Online Self-Help Intervention based on problem-solving therapy)
Description: The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions.
Study NCT04533230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention with prescription feedback
Description: Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
Study NCT04533230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information on treatment guidelines
Description: Written information on treatment guidelines.
Study NCT00005976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00005976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazoloacridine
Study NCT03692871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
Study NCT03658603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracodorsal artery perforator flap
Description: fascio-cutaneous flap used in cases of trauma or burns
Study NCT03658603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: latissimus dorsi flap
Description: musculo-cutaneous flap used in cases of trauma or burns
Study NCT02833948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)
Study NCT02833948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)
Study NCT01153295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis based on symptom criteria
Description: The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
Study NCT01153295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis of exclusion
Description: The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
Study NCT03518645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPN strategy
Description: Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
Study NCT03518645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard strategy
Description: Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
Study NCT02770898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Holistic Health
Description: Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
Study NCT00747032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NYC 0462 Ointment
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Study NCT00747032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Study NCT02487225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
Study NCT02487225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
Study NCT02290457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core strength training
Description: Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only.
Study NCT03209817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red cherry tomato
Description: 300 grams of cherry tomatoes per day for four weeks (each)
Study NCT03209817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yellow cherry tomato
Description: 300 grams of cherry tomatoes per day for four weeks (each)
Study NCT03874728 — intervention group
Intervention type: OTHER
Intervention: Minimal shoes
Description: A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
Study NCT03874728 — intervention group
Intervention type: OTHER
Intervention: Standardised conventional shoes
Description: The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
Study NCT03874728 — intervention group
Intervention type: OTHER
Intervention: Barefoot
Description: Participants will conduct the assessments barefoot.
Study NCT03874728 — intervention group
Intervention type: OTHER
Intervention: Smart shoe insoles
Description: Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
Study NCT02016482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT02016482 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Study NCT02016482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02016482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00783601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + placebo
Description: Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
Study NCT01109147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery
Description: All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
Study NCT01109147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imagery
Description: All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
Study NCT01109147 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenetic sampling
Description: A pharmacogenetic sample will be done with an additional consentment.
Study NCT01109147 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: pharmacogenetic sampling
Description: A pharmacogenetic sample will be done with an additional consentment.
Study NCT00858182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution for nocturnal exchanges
Description: Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
Study NCT00783601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0524 + montelukast
Description: Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
Study NCT00858182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution for diurnal exchanges
Description: Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
Study NCT00842205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon
Description: peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
Study NCT00842205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavarin
Description: ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
Study NCT01161485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing and Counseling
Description: A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study NCT01161485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Testing and Counseling
Description: A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
Study NCT04832945 — intervention group
Intervention type: DRUG
Intervention: Ivermectin 6 Mg Oral Tablet
Description: Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
Study NCT01275092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath robotic-assisted PCI
Description: CorPath 200® robotic-assisted percutaneous coronary intervention
Study NCT03688243 — intervention group
Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
Study NCT01009749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System for Adherence (MESA)
Description: MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
Study NCT01009749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement System for Health (MESH)
Description: Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
Study NCT03393507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
Study NCT03393507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxus + platinum
Description: Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
Study NCT03393507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxus + platinum
Description: Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
Study NCT00605891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)
Study NCT00605891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))
Study NCT00605891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)
Study NCT00605891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
Study NCT00605891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
Study NCT03972410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: 2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
Study NCT03972410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SEDP
Description: 2-4 sessions individual 60-min-long treatment sessions of SEDP
Study NCT00819494 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Skin tests with radiocontrast media
Description: Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
Study NCT00819494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin tests with radiocontrast media
Description: Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
Study NCT01458834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification task
Description: Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
Study NCT01458834 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
Study NCT01797380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for duration of double-blind portion of trial
Study NCT01797380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg po daily for duration of double-blind portion of trial
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: 0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT01161485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.